The objectives ofthe Development Research Program of the DF/HCC Kidney Cancer SPORE are 1) to provide short-term funding for innovative and meritorious research projects in kidney cancer that have the potential to evolve into translational studies, 2) to fund efforts that will complement or enhance the overall scope and quality of the SPORE and 3) to ensure a confinual renewal of high quality and innovative translational research within the SPORE. These projects may be investigator-initiated laboratory or clinical research, or they may be designed to create a shared resource or enhance the research infrastructure of the SPORE. The Program will rely on the infrastructure created by the Administrafion, Evaluafion and Planning Core (Core 1) to accomplish these goals. The process will involve: 1) Identificafion of promising areas of translafional research related to kidney cancer 2) Solicitation of high quality applications addressing these and other areas 3) Selection of worthy projects for funding -Provision of critiques to selected projects -Provision of critiques, encouragement and support for potentially worthy, unselected projects 4) Provision of funds to the selected projects 5) Evaluation of progress and accomplishments ofthe projects including the possibility of 2nd year funding and transition into full project status 6) Evaluafion of the success of the Developmental Program as a whole This process has served us well in the initial SPORE funding period with four Projects in the current grant application (Projects 1, 3, 4 and 5) being based in total or in part on scientific knowledge that emerged from Developmental Projects. Results of the first funding cycle are summarized below. The specific steps in this process are described in more detail thereafter.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-09
Application #
8381288
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
9
Fiscal Year
2012
Total Cost
$134,531
Indirect Cost
$30,320
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
De Velasco, Guillermo; Je, Youjin; Bossé, Dominick et al. (2017) Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 5:312-318
Carey, Christopher D; Gusenleitner, Daniel; Lipschitz, Mikel et al. (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420-2430
Kansy, Benjamin A; Concha-Benavente, Fernando; Srivastava, Raghvendra M et al. (2017) PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res 77:6353-6364
Juneja, Vikram R; McGuire, Kathleen A; Manguso, Robert T et al. (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214:895-904
Ott, Patrick A; Hu, Zhuting; Keskin, Derin B et al. (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217-221
Zhang, Ying; Kurupati, Raj; Liu, Ling et al. (2017) Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32:377-391.e9
Abelin, Jennifer G; Keskin, Derin B; Sarkizova, Siranush et al. (2017) Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity 46:315-326
Zhang, Yiqun; Kwok-Shing Ng, Patrick; Kucherlapati, Melanie et al. (2017) A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell 31:820-832.e3
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Akbay, Esra A; Koyama, Shohei; Liu, Yan et al. (2017) Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol 12:1268-1279

Showing the most recent 10 out of 137 publications